Efficacy and Safety of Huxin Formula in Patients after CABG: A Multicenter, Double-Blind, Randomized Clinical Trial

Abstract

Background: Coronary artery bypass grafting (CABG) is widely used in the treatment of coronary artery disease. A multicenter, double-blind, randomized, controlled clinical trial was designed to evaluate the efficacy and safety of Huxin Formula post CABG. Patients and Methods: 270 inpatients with coronary heart disease participated in this study. CABG patients in the control group were treated with placebo, while patients in the experimental group were treated with Huxin Formula 1 week after the surgery. All patients were treated for 6 months and followed up for another 6 months. The main outcomes (death, nonfatal myocardial infarction, repeat revascularization, and readmission) were assessed 360 days after treatment, and secondary outcomes (frequency and scores of angina pectoris, etc.) were assessed 0, 90, 180, 270, and 360 days after treatment. Results: Our results showed no significant difference between the 2 groups for the primary endpoints. In patients with cardiac function class II (New York Heart Association), the score of angina pectoris was significantly lower (3.88 ± 3.86 vs. 5.45 ± 3.59) and the frequency of angina pectoris attacks was less (0.96 ± 1.01 vs. 1.36 ± 0.94) after 90 days of treatment with Huxin Formula compared to placebo (p < 0.05). In patients with 3 coronary vessel lesions, the cardiac function class (1.14 ± 0.35 vs. 1.05 ± 0.21) after 360 days was significantly higher in the control group compared to the treatment group (p < 0.05). There were no obvious adverse reactions. Conclusion: Huxin Formula may improve cardiac function of patients with 3 coronary vessel lesions and relieve symptoms of patients with cardiac function class II but failed to show superiority in primary outcomes.

Tiaopi huxin recipe improved endothelial dysfunction and attenuated atherosclerosis by decreasing the expression of caveolin‐1 in ApoE‐deficient mice

“…The formulation primarily consists of ginseng (Ginseng Radix et Rhizoma; Araliaceae), tomentose pummelo peel (Citri Grandis Exocarpium; Rutaceae), sanchi (Notoginseng Radix et Rhizoma), P. ternata (Pinelliae Rhizoma), dan-shen root (Salviae Miltiorrhizae Radix et Rhizoma), and cablin patchouli herb (Pogostemonis Herba; Labiatae). Our previous studies showed that TPHXR had a good curative effect in coronary heart disease (Lin et al, 2014) and inhibited the inflammatory response in patients with coronary heart disease and impaired glucose metabolism (Li, He, & Zhao, 2014). In the present study, we used ApoE −/− mice to investigate the potential antiatherosclerotic effects of TPHXR and its influence on the regulation of Cav-1 and the downstream inflammatory response modifications.…”

Phytotherapy - New Developments and Insights into Practice

“…In the section ‘original articles' we are proud to present new research on a rather unknown herbal drug with a long-standing traditional use in Europe [7]. Additionally, there are also 2 clinical trials on Chinese herbal drugs [8,9] which report herbal remedy use in rather severe indications. …”